Boron-11 MRI and MRS of intact animals infused with a boron neutron capture agent.
Boron neutron capture therapy (BNCT) depends on the delivery of boron-containing drugs to a targeted lesion. Currently, the verification and quantification of in vivo boron content is a difficult problem. Boron-11 spectroscopy was utilized to confirm the presence of a dimeric sulfhydryl dodecaborane BNCT agent contained in an intact animal. Spectroscopy experiments revealed that the decay time of transverse magnetization of the boron-11 spins was less than 1 ms which precluded the use of a 2DFT imaging protocol. A back-projection protocol was developed and utilized to generate the first boron-11 image of a BNCT agent in the liver of an intact Fisher 344 rat.
Kabalka
G W
GW
Department of Radiology, University of Tennessee Institute for Biomedical Imaging, Knoxville 37920.
Davis
M
M
Bendel
P
P
D000818:Animals; D001881:Borates / Q000032:analysis* / Q000627:therapeutic use; D008099:Liver / Q000032:analysis*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008297:Male; D009502:Neutrons; D011878:Radiotherapy / Q000379:methods; D051381:Rats; D011916:Rats, Inbred F344; D013440:Sulfides / Q000032:analysis* / Q000627:therapeutic use
D001881:Borates; D013440:Sulfides; C058232:cesium 1,1'-dithiobis(undecahydrododecaborate)